Correvio Pharma (NASDAQ:CORV) will be posting its quarterly earnings results after the market closes on Tuesday, November 6th. Analysts expect Correvio Pharma to post earnings of ($0.20) per share for the quarter.
Correvio Pharma (NASDAQ:CORV) last issued its earnings results on Tuesday, August 14th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.23). Correvio Pharma had a negative return on equity of 230.15% and a negative net margin of 69.75%. The firm had revenue of $6.18 million for the quarter, compared to analyst estimates of $7.16 million. On average, analysts expect Correvio Pharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Shares of NASDAQ:CORV opened at $3.38 on Monday. The company has a current ratio of 4.11, a quick ratio of 3.49 and a debt-to-equity ratio of 2.71. Correvio Pharma has a twelve month low of $1.29 and a twelve month high of $5.24. The company has a market cap of $119.61 million, a PE ratio of -3.76 and a beta of -0.08.
A number of equities analysts have recently weighed in on the company. ValuEngine raised Correvio Pharma from a “hold” rating to a “buy” rating in a research report on Thursday, September 6th. HC Wainwright set a $11.00 target price on Correvio Pharma and gave the stock a “buy” rating in a research report on Thursday, October 25th. Finally, Mackie raised Correvio Pharma from a “hold” rating to a “buy” rating in a research report on Friday, October 12th.
Correvio Pharma Company Profile
Correvio Pharma Corp., a specialty pharmaceutical company, provides various products to meet the needs of acute care physicians and patients worldwide. It develops, acquires, and commercializes various brands for the in-hospital acute care market segment. The company's portfolio of marketed brands include Xydalba (dalbavancin hydrochloride) for the treatment of acute bacterial skin and skin structure infections; Zevtera/Mabelio (ceftobiprole medocaril sodium), a cephalosporin antibiotic for the treatment of community and hospital-acquired pneumonia; and Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm.
Read More: What is the Dividend Aristocrat Index?
Receive News & Ratings for Correvio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Correvio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.